We help discover multi-biomarker panels which are
more robust, highly specific and sensitive


Our proprietary algorithms and pipelines
allow us to deliver unique multi-biomarker panels


Machine learning, evolutionary algorithms and
fuzzy logic are changing the face of
multi-biomarker panels discovery

The truth is in your data. We help find it!

Imagine providing multi-type and unbalanced data sets and discovering multi-biomarker panels in 48 hours, even with missing data. SimplicityBio makes this possible today! Answer your production, regulatory and IP requirements with robust, highly specific and sensitive multi-biomarker panels.

Why multiple biomarkers?

The advantages of a multi-biomarker approach in comparison to a single biomarker one are based on the premise that the single-valued index, with its aggregated information from complementary biomarkers, will outperform each of its component biomarkers used individually.

Multi-biomarker panels approach

We develop combinations of panels to produce a final panel. This "modular redundancy" approach allows the correction and/or compensation of a model that is not deemed efficient by other models; thereby it improves considerably the reliability of the final answer.

How do we do it?

We are able to test billions of hypotheses and biomarker combinations in order to find the most accurate and robust panels. These biomarkers are selected in our high performance software platform for in-silico multi-biomarker panel discovery.

Our Clients

"I have no hesitation in highly recommending SimplicityBio as a great partner. They have been with us in every step of our project over the last two years, from discovery of candidate biomarker signatures all the way through to their validation. Their unique platform delivered robust signatures that kept performing even when switching from plasma to serum and before being optimised. They have helped us extract the best from our data, exploring it fully in both the technical and commercial areas. This gave us the outcomes we needed and the confidence to raise funds and move forward. Without SimplicityBio's technology (and team support) it would not have been possible. Their responsiveness and commitment to understand our needs makes them a partner of choice"

Dr Brad Walsh
CEO | Mi)nomic International Ltd
Adjunct Professor | Macquarie University

"We were very enthusiastic about working together and discovering new original and non-traditional methods to analyze our data. In case we want to implement this type of approach in any other study, we won’t hesitate to come back to SimplicityBio."

Sophie Blein Ph.D
Biostatistics/Bioinformatics | bioMérieux
Medical Diagnostics Discovery Department | MD3


Poster, MiCheck-01 prospective trial results at ASCO GU Cancers Symposium 2018

SimplicityBio’s customer Minomic presents the MiCheck assay results. The 350-patient study highlights the test’s performance in differentiating Aggressive from Non-Aggressive Prostate Cancer. Algorithm development are ongoing.

SimplicityBio is Awarded the CTI Start-Up Label

SimplicityBio's CTI Start-Up journey was crowned by the CTI Label, a seal of quality, achievement, and a sign of credibility and readiness for sustainable growth. The label is awarded after a technical, IP and financial assessment of SimplicityBio and a final presentation to seasoned entrepreneurs.

SimplicityBio joins EU-funded (EUROSTARS) HeartLinc Program

SimplicityBio will apply its expertise in the frame of this €3.2 million research program, the consortium will develop an innovative in vitro diagnostic (IVD) test to assess the risk of developing heart failure (HF) after acute myocardial infarction (AMI). The test will be based on a unique profile of long noncoding RNAs (lncRNA).